Page last updated: 2024-08-26

fulvestrant and Lymphangiomyomatosis

fulvestrant has been researched along with Lymphangiomyomatosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Henske, EP; Li, C; Mancini, JD; Morrison, TA; Parkhitko, A; Silverman, EK; Sun, Y; Yu, JJ; Zhang, E; Zhou, X	1

Other Studies

1 other study(ies) available for fulvestrant and Lymphangiomyomatosis

Article	Year
Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:1 Topics: Airway Remodeling; Animals; Antineoplastic Agents; Collagen Type IV; Drug Evaluation, Preclinical; Estradiol; Extracellular Matrix; Female; Fulvestrant; Lung; Lung Neoplasms; Lymphangioleiomyomatosis; Male; Matrix Metalloproteinase 2; Mice; Mice, SCID; Rats; Receptors, Estradiol; Survival Analysis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2013

Article

Year

Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:1

Topics: Airway Remodeling; Animals; Antineoplastic Agents; Collagen Type IV; Drug Evaluation, Preclinical; Estradiol; Extracellular Matrix; Female; Fulvestrant; Lung; Lung Neoplasms; Lymphangioleiomyomatosis; Male; Matrix Metalloproteinase 2; Mice; Mice, SCID; Rats; Receptors, Estradiol; Survival Analysis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2013